Impedimed L-Dex® Analysis for Lymphedema

Impedimed - L-Dex® Analysis for Lymphedema

Supplier: ImpediMed Limited

L-Dex® Analysis for Lymphedema

The L‑Dex score, only available from ImpediMed, is designed to detect small lymphedema-related fluid changes in the limbs.

In Stock

Features of this product

The L-Dex score, only available from ImpediMed, is designed to detect small lymphedema-related fluid changes in the limbs.
L-Dex compares the fluid in a limb at-risk for lymphedema to a healthy limb in order to help detect lymphedema.
FDA-cleared for unilateral and bilateral secondary lymphedema of the arms and legs, in women and men.
L-Dex is validated to detect lymphedema at its earliest, subclinical stage
Detects fluid changes as small as 36 ml (2.4 tablespoons)1
Validated against lymphoscintigraphy2
80% Sensitive and 90% Specific in detecting subclinical lymphedema following cancer surgery with a 6.5 change from a pre-treatment baseline3
81% lower incidence of chronic cancer-related lymphedema with BIS L-Dex monitoring and intervention than with circumference monitoring in a meta-analysis of 67,000 patients4
Statistically lower rates of chronic lymphedema in high-risk patients and short-term and long-term follow-up4 Consistent reduction in lymphedema progression, study after study

To contact ImpediMed Limited about Impedimed L-Dex® Analysis for Lymphedema use Get a quote.

Features of this product

The L-Dex score, only available from ImpediMed, is designed to detect small lymphedema-related fluid changes in the limbs.
L-Dex compares the fluid in a limb at-risk for lymphedema to a healthy limb in order to help detect lymphedema.
FDA-cleared for unilateral and bilateral secondary lymphedema of the arms and legs, in women and men.
L-Dex is validated to detect lymphedema at its earliest, subclinical stage
Detects fluid changes as small as 36 ml (2.4 tablespoons)1
Validated against lymphoscintigraphy2
80% Sensitive and 90% Specific in detecting subclinical lymphedema following cancer surgery with a 6.5 change from a pre-treatment baseline3
81% lower incidence of chronic cancer-related lymphedema with BIS L-Dex monitoring and intervention than with circumference monitoring in a meta-analysis of 67,000 patients4
Statistically lower rates of chronic lymphedema in high-risk patients and short-term and long-term follow-up4 Consistent reduction in lymphedema progression, study after study

To contact ImpediMed Limited about Impedimed L-Dex® Analysis for Lymphedema use Get a quote.